Case Report

Sarcotubular Myopathy Due to Novel TRIM32 Mutation in Association with Multiple Sclerosis

Margarita Marchuk 1,*, Tetiana Dovbonos 2,*, Halyna Makukh 3, Orest Semeryak 4 and Yevheniya Sharhorodska 5

Department of Neurology No.2, Kyiv City Clinical Hospital No.4, 03110 Kiev, Ukraine

Department of Neurology, O.O. Bogomolets National Medical University, 13 Shevchenko Blvd., 01601 Kyiv, Ukraine

Institute of Hereditary Pathology of National Academy of Medical Sciences of Ukraine, 31A Lysenka Str., 79008 Lviv, Ukraine; makukh_halyna@ukr.net

Center for Neuromuscular and Peripheral Nervous System Diseases, Lviv Regional Clinical Hospital, 7 Chernihivska Str., 79010 Lviv, Ukraine; dr.orchyk@gmail.com

Institute of Hereditary Pathology of National Academy of Medical Sciences of Ukraine, 31A Lysenka Str., 79008 Lviv, Ukraine; gendoctor86@gmail.com

* Correspondence: dr.marchuk@ukr.net (M.M.); tetanatdovbonos@ukr.net (T.D.)

Abstract: Azerbaijani 28-year-old female showed weakness (MRC (Medical Research Council Scale for Muscle Strength) grade 4 in the proximal part of the upper and MRC grade 2–3 in the lower extremities), difficulty in stair lifting, positive symptom of Hoover’s rising, «waddling gait», decline deep reflexes symmetrical, lack of surface reflexes, positive Babinsky’s reflex on the right, urinary incontinence during sneezing, prolonged walking and exercise from puberty. Additional methods made it possible to identify minor violations of conduction of the left ventricle, electromyography signs of primary muscular disease with predominant involvement of the proximal muscles of the lower extremities, elevation of serum creatine kinase (746.81 U/l), active foci of demyelination in the left frontal lobe, intrathecal synthesis of oligoclonal IgG bands (type 2) in cerebrospinal fluid, atrophy and fatty degeneration of all muscles of the shins, homozygous Variant of Uncertain Significance (VUS) c.1855C > T (p.Pro619Ser) in TRIM32 gene and heterozygous VUS c.2300C > G (p.Thr767Arg) in KIF5A, c.2840G > A (p.Arg947Lys) in MYH2, c.1502G > C (p.Gly501Ala) in POMT1 genes. Comparison of the phenotypes of the mutations that have been identified with the clinical picture of the patient suggests that VUS c.1855C > T (p.Pro619Ser) in the TRIM32 gene can be pathological. Summarizing, it can be argued that the cause of the identified disorders is a homozygous variant c.1855C > T (p.Pro619Ser) in TRIM32 gene that causes LGMDR8 in a patient with MS.

Keywords: LGMD2H; LGMD R8; Limb-Girdle Muscular Dystrophy 2H; sarcotubular myopathy; TRIM32; muscular dystrophy; multiple sclerosis; Hoover’s rising; waddling gait; next-generation sequencing

1. Introduction

Trirpartite motif-containing protein 32 (TRIM32) is a member of the TRIM ubiquitin E3 ligases which ubiquitinates different substrates in muscle including sarcromeric proteins. Mutations in TRIM32 have been associated to Limb-Girdle Muscular Dystrophy 2H (LGMD2H) and Sarcotubular Myopathy, a form of distal myopathy with peculiar features in muscle biopsy, now considered in the spectrum of LGMD2H. [1]. TRIM32 mutations were initially described in the Manitoba Hutterite population (41 patients) of North America presenting with a phenotype of the LGMD2H and the first mutation identified was the c.1459G > A (p. Asp487Asn) [2]. However, in 2018 after the overall development of molecular-genetic research, classification of LGMD became reorganized resulting in renaming LGMD2H to Limb-Girdle Muscular Dystrophy, Autosomal Recessive 8 (LGMDR8) [3].
For today, LGMDR8 is a rare muscular dystrophy due to mutation in TRIM32 gene with a wide clinical presentation spectrum [2,4–6]. Additionally, the problem of comorbidity is not covered in the literature, especially for multiple sclerosis (MS) and LGMDR8.

2. Case Report

The collection of complaints of Azerbaijani 28-year-old female showed weakness and fatigue of limb muscles, difficulty in stair climbing, prolonged walking and exercise. For the first time in physical education classes at school, she noticed that she could not fulfill standards that were simple for others. Since puberty, weakness in the lower extremities has progressed. The patient was limited in the ability to walk for a long time, gradually there was a significant difficulty when climbing stairs, getting up from a chair, then finally she could not rise from a squatting position without the support on the objects around her or the help of others.

During the neurological examination there was detected decrease in strength mainly in the proximal part of the upper (Medical Research Council Scale for Muscle Strength - MRC grade 4) and to a greater extent in the lower extremities (MRC grade 2–3), positive symptom of Hoover’s rising, «waddling gait», minor hypotrophy of the proximal limb muscles, decline of deep reflexes symmetrical.

Additionally, the neurologist’s attention was drawn to the small-amplitude nystagmus, lack of surface reflexes, positive Babinsky’s reflex on the right, urinary incontinence during sneezing. The discovered symptoms prompted specialists to conduct magnetic resonance imaging (MRI) of the brain. There were revealed active foci of demyelination in the left frontal lobe (Figure 1a). Re-examination after 2 months revealed multiple (>10) rounded and elongated foci hyperintensive on T2-weighted imaging (T2WI), fluid-attenuated inversion recovery (FLAIR) and short TI inversion recovery, iso- and hypointensive on T1-weighted imaging (T1WI), with a diameter of 2.5 mm to 5.8 mm, located periventricularly and subcortically in the white matter of the left temporal lobe and parietal lobes, frontal lobes, mostly in the left frontal lobe, as well as a decrease in the size of a previously active lesion and the appearance of new lesions in the right frontal and parietal regions. The isoelectric focusing detected an intrathecal synthesis of oligoclonal IgG bands (type 2) in cerebrospinal fluid. The results obtained confirm the diagnosis of relapsing-remitting MS.

![Figure 1. (a) Sagittal T2-weighted MRI scan of the brain shows active foci of demyelination in the left frontal lobe (yellow circle); (b) Sagittal T2 TIRM dark fluid MRI scan shows moderate tongue muscle atrophy.](image-url)
However, the etiology of progressive symmetrical girdle weakness of the upper and lower extremities remained unknown.

Electromyography (EMG) revealed the signs of primary muscular disease with predominant involvement of the proximal muscles of the lower extremities.

Electrocardiography revealed minor violations of myocardial conduction of the left ventricle.

Biochemical analysis showed elevation of serum creatine kinase (746.81 U/l).

MRI of the both shins revealed signs of muscular atrophy and fatty degeneration (Figures 2 and 3) and MRI of the head shows moderate tongue muscle atrophy (Figure 1b). The MRI signal from other soft tissues is not changed.

Figure 2. (a) Axial T1-weighted MRI scan with diffuse increase of signal intensity from all muscles of the both shins; (b) Axial T2 weighted MRI scan with diffuse increase of signal intensity from all muscles of the both shins.

Figure 3. Axial fat-saturated proton density-weighted MRI scan with diffuse decrease of signal intensity from all muscles of the both shins.

Tandem mass spectrometry from dried blood spot found a normal amount of alpha-1,4 glucosidase activity which made it possible to exclude the Pompe disease.

Next-generation sequencing (NGS) was chosen for more accurate diagnostics. Genomic DNA obtained from the submitted sample was enriched for targeted regions using a hybridization-based protocol, and sequenced using Illumina technology. Sequence analysis and deletion/duplication testing of the 305 genes Invitae Comprehensive Neuromuscular Disorders Panel was implemented. All targeted regions were sequenced with ≥50× depth or supplemented with additional analysis. All clinically significant observations were confirmed by orthogonal technologies. Confirmation technologies included Sanger sequencing, Multiplex ligation-dependent probe amplification. Technical component of confirmatory sequencing was performed by Invitae Corporation (San Francisco, CA, USA, 94103, #05D2040778).

NGS showed homozygous Variant of Uncertain Significance (VUS) c.1855C > T (p.Pro619Ser) in TRIM32 gene and heterozygous VUS c.2300C > G (p.Thr767Arg) in KIF5A, c.2840G > A (p.Arg947Lys) in MYH2, c.1502G > C (p.Gly501Ala) in POMT1 genes (Table 1).
### Table 1. Identified variants of uncertain significance.

| Gene   | Variant                      | Zygosity  | Variant Classification |
|--------|------------------------------|-----------|------------------------|
| KIF5A  | c.2300C > G (p.Thr767Arg)    | heterozygous | Uncertain Significance |
|        | c.2840G > A (p.Arg947Lys)   | heterozygous | Uncertain Significance |
| MYH2   | c.1502G > C (p.Gly501Ala)   | heterozygous | Uncertain Significance |
| POMT1  | c.1855C > T (p.Pro619Ser)   | homozygous | Uncertain Significance |

Variant c.1855C > T (p.Pro619Ser) is located in exon 2 of TRIM32 gene and caused the replacement of proline with serine at codon 619 of the TRIM32 protein (p.Pro619Ser). The proline residue is highly conserved and there is a moderate physicochemical difference between proline and serine. This variant is not present in population databases and it has not been reported in the literature in individuals with TRIM32-related conditions.

Variant c.2300C > G (p.Thr767Arg) of KIF5A gene causes the replacement of threonine with arginin at codon767 of the KIF5A protein (p.Thr767Arg). This variant is present in population databases (rs765493045, ExAC 0.006%).

The comparison of the phenotypes presented in Table 2 with the clinical picture of the patient suggests that VUS c.1855C > T (p.Pro619Ser) in the TRIM32 gene can be pathological.

### Table 2. Phenotypes of the detected mutations.

| Gene                    | Diagnosis                                      | Phenotype                                      |
|-------------------------|------------------------------------------------|------------------------------------------------|
| KIF5A (Kinesin heavy chain isoform 5A) | Intractable neonatal myoclonus (MedGen UID: 934625) | - Intractable myoclonic seizures  
- intermittent apnea  
- abnormal eye movements  
- pallor of the optic nerve  
- lack of developmental progress  
- appear after birth  
- progressive leukoencephalopathy (brain imaging)  
- death in infancy [9] |
| Autosomal dominant hereditary spastic paraplegia 10 (SPG10) (MedGen UID: 349003) | 'Pure' spastic paraplegia: lower limb spasticity, hyperreflexia, extensor plantar responses  
- variable involvement of the upper limbs  
- appear in childhood or young adulthood  
- axonal sensorimotor peripheral neuropathy: distal sensory impairment, muscle atrophy is reminiscent of Charcot-Marie-Tooth disease type 2  
- parkinsonism or cognitive decline [7,8] |
| ALS25 (Amyotrophic lateralsclerosis 25) (MedGen UID: 1534540) | Adult onset of focal asymmetric involvement of upper and lower motor neuron systems with later generalization  
- bulbar motor involvement  
- rapidly progressive muscle weakness  
- death due to respiratory failure [10] |
Table 2. Cont.

| Gene                        | Diagnosis                                                                 | Phenotype                                                                                                                                 |
|-----------------------------|---------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| MYH2 (Myosin-2)             | Autosomal dominant and recessive inclusion body myopathy type 3 (MYPOP) (MedGen UID: 381340) | • Proximal myopathy
• ophthalmoplegia
• childhood onset of symptoms
• slowly progressive or nonprogressive [11,12] |
| POMT1 (Protein O-mannosyl-transferase 1) | Autosomal recessive muscular dystrophy-dystroglycanopathy type A1 (MDDGA1) (MedGen UID: 75553) | • Brain and eye malformations: mental retardation, congenital muscular dystrophy, and early death
• cobblestone (type II) lissencephaly, cerebellar malformations, and retinal malformations
• macrocephaly or microcephaly, hypoplasia of midline brain structures, ventricular dilatation, microphthalmia, cleft lip/palate, and congenital contractures [13]
• those with a more severe phenotype characterized as Walker-Warburg syndrome often die within the first year of life [14] |
|                            | Autosomal recessive muscular dystrophy-dystroglycanopathy type B1 (MDDGB1) (MedGen UID: 461765) | • hypotonia at birth
• joint contractures
• severe psychomotor retardation
• inability to walk
• striking enlargement of the calf and quadriceps muscles
• absent speech
• mental retardation
• enlargement of the cisterna magna and cerebellar hypoplasia [15,16]
• leg hypertrophy
• microcephaly
• grossly delayed motor milestones
• facial weakness with tendency to keep the mouth open
• mild macroglossia
• lower limb stiffness
• increased serum creatine kinase [17]
• autistic features
• diffuse muscle wasting
• scoliosis
• cardiomyopathy [18] |
|                            | Autosomal recessive muscular dystrophy-dystroglycanopathy type C1 (MDDGC1) (MedGen UID: 332193) | • early motor milestones
• age at onset ranged from 1 to 6 years, with difficulty in walking and climbing stairs
• slow progression, proximal muscle weakness
• mild muscle hypertrophy
• increased serum creatine kinase
• microcephaly
• mental retardation (IQ range 50 to 76) [19]
• shortness of breath
• easy fatigability
• left ventricular hypertrophy and dilation of the ventriculars, systolic dysfunction
• calf and thigh hypertrophy, relative wasting of the scapulohumeral girdle
• myalgias in the shoulder girdle
• calf hypertrophy
• normal cognition [18] |
Table 2. Cont.

| Gene | Diagnosis | Phenotype |
|------|-----------|-----------|
| Autosomal recessive Bardet-Biedl syndrome (BBS) (MedGen UID: 395295) | | • Obesity  
• polydactyly  
• renal anomalies  
• retinopathy  
• hypogonadism  
• learning disabilities [20] |
| TRIM32 (Tripartite motif containing 32) | | • Nonprogressive muscular weakness from infancy [21]  
• slowly progressive dystrophy in the quadriceps and pelvic girdle musculature with facial features  
• waddling gait  
• difficulty rising from the squatting position  
• ‘flat smile’ [4]  
• creatine kinase (CK) levels more than 4 times the upper limit of normal. Asymptomatic patients with extremely elevated CK levels (more than 15 times the upper limit of normal) were also considered affected [5]  
• scapular winging  
• moderate hypertrophy of the calves  
• absent deep tendon reflexes  
• exercise-induced myalgia [22]  
• respiratory weakness  
• chronic keratitis  
• paresthesias  
• lost the ability to walk [23] |
| Limb-girdle muscular dystrophy type 2H (LGMD2H) or Limb-girdle Muscular Dystrophy R8 (LGMDR8) (MedGen UID:78750) | | |
Insofar as the systematic review demonstrated that effects on the clinical course and the long-term safety of gene transfer, myoblast transplantation, neutralizing antibody to myostatin, or growth hormone are yet to be determined the best supportive strategy includes:

• performing pulmonary function testing, detection of excessive daytime somnolence, nonrestorative sleep, episodes of syncope, near-syncope, palpitations, symptomatic or asymptomatic tachycardia or arrhythmias, or signs and symptoms of cardiac failure for cardiology evaluation (Level B).
• realization of periodic assessments by a physical and occupational therapist for symptomatic and preventive screening (Level B).
• combination of aerobic exercise with a supervised submaximal strength (Level C).
• practicing gentle, low-impact aerobic exercise (swimming, stationary bicycling) to improve cardiovascular performance, increase muscle efficiency, and lessen fatigue (Level C).
• adequate hydration, no exercise to exhaustion, and avoiding supramaximal, high-intensity exercise (Level C).
• detection of warning signs of overwork weakness and myoglobinuria, which include feeling weaker rather than stronger within 30 minutes after exercise, excessive muscle soreness 24–48 hours following exercise, severe muscle cramping, heaviness in the extremities, and prolonged shortness of breath (Level B) [25].

Expectedly, the weakness of pelvic girdle and shoulder muscles is in a state of slow progression. However, despite the worsening, she successfully graduated from university, passed the gestation period of her second child and had a cesarean section. The patient walks on her own, does not require assistance when climbing a short set of stairs, takes care of herself, and helps family members. She is regularly monitored by doctors, undergoes preventive examinations, is engaged in physical exercises and periodically receives specific treatment for MS.

3. Discussion

We describe a novel mutation in TRIM32 gene in an adult patient who was presented with the combination of MS and a moderate limb muscles weakness which was regarded as LGMDR8.

The diagnosis of MS is confirmed by the 2017 McDonald criteria, according to which the presence of 1 attack and clinical evidence of 2 or more lesions in combination with new T2 or enhancing MRI lesion compared to baseline scan (without regard to timing of baseline scan) or oligoclonal bands in cerebrospinal fluid is the basis for the diagnosis [26]. With regard to limb muscle weakness in MS, systematic review and meta-analysis of cross-sectional studies confirmed the presence of neurophysiological decrements, manifest only as impaired maximum voluntary contraction force, reduced skeletal muscle voluntary activation and greater motor fatigability [27]. However, in our case, neurophysiological examination revealed a “myopathic type” of motor unit recruitment, which is EMG-characteristic of primary muscle disease.

The NGS analysis revealed in the patient the VUS in four genes: c.2300C > G (p.Thr767Arg) in KIF5A, c.2840G > A (p.Arg947Lys) in MYH2, c.1502G > C (p.Gly501Ala) in POMT1 and c.1855C > T (p.Pro619Ser) in TRIM32. None of these variants were reported in patients with neuromuscular disorders.

Compare to all heterozygous VUS which were discovered only c.1855C > T (p.Pro619Ser) in TRIM32 is homozygous. As known the POMT1 gene is associated with autosomal recessive disorder. The pathogenic variants in KIF5A and MYH2 genes are associated with autosomal dominant conditions but not one (hereditary spastic paraplegia or body myopathy type 3) is clinically consistent with symptoms of the patient. Moreover, the replacement of arginine with lysine at codon 947 of the MYH2 protein (p.Arg947Lys) leads to small physicochemical difference between amino acids.
The homozygous c.1855C > T (p.Pro619Ser) variant in TRIM32 gene supports the hypothesis of autosomal recessive conditions. There were no cases of neuromuscular conditions among patients’ relatives. The patient is of Azerbaijani ethnicity and both of her parents have the same origin. It is important to emphasize that Azerbaijani population has high level of inbreeding marriage, which may cause the high risk of homozygosity for pathogenic variants [28]. We hypothesize that both parents of the patient have the same ancestors with c.1855C > T (p.Pro619Ser) variant in TRIM32 gene. Unfortunately, the patient’s relatives refused to undergo examination due to the absence of symptoms. Genetic counseling did not discourage the relatives of the importance of testing. Therefore, the investigation of the pathogenic potential of the identified variants can be promising in the process of further monitoring of the patient. The variant is not described in clinical database and was not reported in the literature. LGMDR8 has autosomal recessive inheritance and cause by homozygous or compound heterozygous mutations in TRIM32 gene. In the case we describe homozygous mutation in patient with clinical phenotype of LGMDR8.

Our data support the reclassification of homozygous variant c.1855C > T (p.Pro619Ser) in TRIM32 gene as pathogenic.

Author Contributions: Conceptualization, T.D., H.M., O.S., Y.S. and M.M.; methodology, H.M.; validation, T.D., H.M. and O.S.; formal analysis, M.M.; investigation, M.M.; resources, T.D.; data curation, H.M.; writing—original draft preparation, M.M. and H.M.; writing—review and editing, T.D., H.M. and O.S.; visualization, M.M.; supervision, T.D., H.M. and O.S.; project administration, T.D.; funding acquisition, Y.S. and M.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Informed Consent Statement: Written informed consent has been obtained from the patient to publish this paper.

Acknowledgments: We thank the patient and her family for consenting to clinical advice, diagnosis, and data sharing with the scientific community. We also thank the Department of Neurology of the O.O. Bogomolets National Medical University (Kyiv) headed by Larisa Sokolova for laying a solid foundation of knowledge and clinical practice for recognizing rare clinical cases in a doctor’s practice. We are grateful to the public organization “Ukrainian Association of Neuromuscular Diseases and Diseases of the Peripheral Nervous System” (Lviv), headed by neurologist Orest Semeryak, for providing valuable information to improve the level of qualifications at annual international conferences.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Panicucci, C.; Traverso, M.; Baratto, S.; Romeo, C.; Iacomino, M.; Gemelli, C.; Tagliafico, A.; Broda, P.; Zara, F.; Bruno, C.; et al. Novel TRIM32 mutation in sarcotubular myopathy. Acta Myol. 2019, 38, 8–12. [CrossRef]
2. Frosk, P.; Weiler, T.; Nylen, E.; Sudha, T.; Greenberg, C.R.; Morgan, K.; Fujisawa, T.M.; Wrogemann, K. Limb-Girdle Muscular Dystrophy Type 2H Associated with Mutation in TRIM32, a Putative E3-Ubiquitin–Ligase Gene. Am. J. Hum. Genet. 2002, 70, 663–672. [CrossRef]
3. Straub, V.; Murphy, A.; Udd, B.; Corrado, A.; Aymé, S.; Bönneman, C.; de Visser, M.; Hamosh, A.; Jacobs, L.; Khizanishvili, N.; et al. 229th ENMC international workshop: Limb girdle muscular dystrophies—Nomenclature and reformed classification Naarden, the Netherlands, 17–19 March 2017. Neuromuscul. Disord. 2018, 28, 702–710. [CrossRef]
4. Shokeir, M.H.K.; Kobrinsky, N.L. Autosomal recessive muscular dystrophy in Manitoba Hutterites. Clin. Genet. 2008, 9, 197–202. [CrossRef]
5. Weiler, T.; Greenberg, C.R.; Zelinski, T.; Nylen, E.; Coghlann, G.; Crumley, M.J.; Fujisawa, T.M.; Morgan, K.; Wrogemann, K. A Gene for Autosomal Recessive Limb-Girdle Muscular Dystrophy in Manitoba Hutterites Maps to Chromosome Region 9q31-q33: Evidence for Another Limb-Girdle Muscular Dystrophy Locus. Am. J. Hum. Genet. 1998, 63, 140–147. [CrossRef]
6. Bushby, K.M.D. Making sense of the limb-girdle muscular dystrophies. Brain 1999, 122, 1403–1420. [CrossRef] [PubMed]
7. Goizet, C.; Boukhiris, A.; Mundwiller, E.; Tallaksen, C.; Forlani, S.; Toutain, A.; Carriere, N.; Depienne, C.; Durr, A.; Stevanin, G.; et al. Complicated forms of autosomal dominant hereditary spastic paraplegia are frequent in SPG10. Hum. Mutat. 2008, 30, E376–E385. [CrossRef] [PubMed]
